Aavocyte specializes in T cell immunotherapy for solid tumors, utilizing a recombinant adeno-associated virus (rAAV) based platform. This innovative approach involves the use of rAAV vectors that carry tumor antigen genes, which are designed to infect the patient's monocytes. Once infected, these monocytes differentiate into antigen-presenting cells, specifically dendritic cells. These dendritic cells then activate naive CD8+ T cells, transforming them into antigen-specific cytotoxic T lymphocytes (CTLs) that can effectively target and eliminate tumor cells while sparing normal cells. Aavocyte's technology boasts a high infection efficiency of over 80% and is capable of targeting multiple cancers through a flexible combination of vectors.

The company's pipeline highlights the establishment of a vector library containing 35 rAAV/antigen vectors, which allows for the development of customized T cell products with enhanced efficacy and reduced side effects. Aavocyte's therapy is designed to address a wide range of solid tumors, including prostate, lung, intestinal, kidney, cervical, gastric, skin, and breast cancers, among others. The technology is recognized for its unique advantages, such as the ability to disrupt tumor blood vessel formation and its broad applicability across more than 20 solid tumors. Additionally, Aavocyte emphasizes outpatient convenience and the safety profile of rAAV, which is acknowledged by regulatory bodies like the FDA and NIH.

United States

Aavocyte, Inc. is a biotech company registered in the State of Washington in 2019. 



Aavocyte specializes in developing various precise targeting T cell immunotherapy products to treat solid tumors.

Aavocyte

Company Details